Cytokinetics is currently in the midst of a sale process, faces a pivotal crossroads with speculation looming on potential suitors,...
Read moreDetailsEven though we are in the beginning of 2024, small-cap stocks have already stolen the spotlight from their larger counterparts,...
Read moreDetailsDelta Air Lines' recent nosedive stirred investor concern, casting a shadow over the entire travel sector.
Read moreDetailsTech player, PagerDuty has entered the spotlight due to a Bloomberg report that unveiled the company's consultation with advisers over...
Read moreDetailsSo far, January has been a challenging month for Wall Street, and today was no exception, with investor confidence drooping...
Read moreDetailsJanuary’s performance so far has been a rollercoaster ride filled with ups and downs. Last week’s turnaround has spurred investor...
Read moreDetailsClinical stage biopharma small-cap, Harpoon Therapeutics has entered the spotlight with pharma giant, Merck agreeing to acquire the company for...
Read moreDetailsDecember's Consumer Price Index (CPI) data is in, and it brought a mixed bag of news for investors and consumers...
Read moreDetailsThe first-ever U.S. spot bitcoin ETFs began trading on Thursday, January 11th, 2024, marking a long-awaited milestone for the cryptocurrency...
Read moreDetailsIn a groundbreaking move, pharmaceutical giant Johnson & Johnson has set the stage for a significant leap forward in cancer...
Read moreDetailsThese Next Steps are EXTREMELY IMPORTANT because the only way to get our Featured Top Stock Alerts is to reply back to the message you just received by answering YES.
CLICK HERE TO REPLY BACK
YES ON YOUR CELL PHONE
To make sure you are in, please check your cell phone for a message from 16462224464 (make sure you save that number on your contacts under "StockTips") If you don't see the message check "Unknown Senders" on your phone.
If you did not receive the text message on your cell phone, then grab your phone right now and text the word "MOMO" to "16462224464"
© 2022 OpenEquity Research - Investment-Grade Research for the rest of us.
© 2022 OpenEquity Research - Investment-Grade Research for the rest of us.